High YKL-40 is associated with poor survival in patients with renal cell carcinoma: a novel independent prognostic marker

References

• Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ. 2014;349:g4797.
   PubMed Web of Science ®Google Scholar
• Quinn DI, Lara PNJ. Renal-cell cancer-targeting an immune checkpoint or multiple kinases. N Engl J Med. 2015;373:1872–1874.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–1813.
   PubMed Web of Science ®Google Scholar
• Lee CG, Da Silva CA, Dela Cruz CS, et al. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol. 2011;73:479–501.
   PubMed Web of Science ®Google Scholar
• Sunela KL, Kataja MJ, Lehtinen ET, et al. Prognostic factors and long-term survival in renal cell cancer patients. Scand J Urol Nephrol. 2009;43:454–460.
   PubMed Web of Science ®Google Scholar
• Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207–214.
   PubMed Web of Science ®Google Scholar
• Guinan P, Sobin LH, Algaba F, et al. TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80:992–993.
   PubMed Web of Science ®Google Scholar
• Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997;183:131–133.
   PubMed Web of Science ®Google Scholar
• Mostofi FK, Davis CJ. In collaboration with L. H. Sobin and Pathologists in 6 Countries. Histological typing of kidney tumours. World Health Organization. International histological classification of tumours, 2nd ed. Berlin, Germany: Springer; 1998.
   Google Scholar
• Renkema GH, Boot RG, Au FL, et al. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem. 1998;251:504–509.
   PubMedGoogle Scholar
• Fusetti F, Pijning T, Kalk KH, et al. Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39. J Biol Chem. 2003;278:37753–37760.
   PubMed Web of Science ®Google Scholar
• Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem. 1993;268:25803–25810.
   PubMed Web of Science ®Google Scholar
• Vuolteenaho K, Leppänen T, Kekkonen R, et al. Running a marathon induces changes in adipokine levels and in markers of cartilage degradation-novel role for resistin. PLoS One. 2014;9:e110481.
   PubMed Web of Science ®Google Scholar
• Väänänen T, Koskinen A, Paukkeri EL, et al. YKL-40 as a novel factor associated with inflammation and catabolic mechanisms in osteoarthritic joints. Mediators Inflamm. 2014;2014:215140.
   PubMed Web of Science ®Google Scholar
• Väänänen T, Vuolteenaho K, Kautiainen H, et al. YKL-40, a novel marker of disease activity in rheumatoid arthritis: the NEO-RACo study. Scand J Rheumatol. 2015;44:524–528.
   PubMed Web of Science ®Google Scholar
• Johansen JS, Jensen BV, Roslind A, et al. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev. 2006;15:194–202.
   PubMed Web of Science ®Google Scholar
• Zhang JP, Yuan HX, Kong WT, et al. Increased expression of chitinase 3-like 1 and microvessel density predicts metastasis and poor prognosis in clear cell renal cell carcinoma. Tumour Biol. 2014;35:12131–12137.
   PubMed Web of Science ®Google Scholar
• Berntsen A, Trepiakas R, Wenandy L, et al. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. J Immunother. 2008;31:771–780.
   PubMed Web of Science ®Google Scholar
• Diefenbach CS, Shah Z, Iasonos A, et al. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecol Oncol. 2007;104:435–442.
   PubMed Web of Science ®Google Scholar
• Mitsuhashi A, Matsui H, Usui H, et al. Serum YKL-40 as a marker for cervical adenocarcinoma. Ann Oncol. 2009;20:71–77.
   PubMed Web of Science ®Google Scholar
• Tschirdewahn S, Reis H, Niedworok C, et al. Prognostic effect of serum and tissue YKL-40 levels in bladder cancer. Urol Oncol. 2014;32:663–669.
   PubMed Web of Science ®Google Scholar
• Zhu CB, Chen LL, Tian JJ, et al. Elevated serum YKL-40 level predicts poor prognosis in hepatocellular carcinoma after surgery. Ann Surg Oncol. 2012;19:817–825.
   PubMed Web of Science ®Google Scholar
• Jeon HG, Choo SH, Sung HH, et al. Small tumour size is associated with new-onset chronic kidney disease after radical nephrectomy in patients with renal cell carcinoma. Eur J Cancer. 2014;50:64–69.
   PubMed Web of Science ®Google Scholar
• vom Dorp F, Tschirdewahn S, Niedworok C, et al. Circulating and tissue expression levels of YKL-40 in renal cell cancer. J Urol. 2016;195:1120–1125.
   PubMed Web of Science ®Google Scholar
• Mickley A, Kovaleva O, Kzhyshkowska J, et al. Molecular and immunologic markers of kidney cancer-potential applications in predictive, preventive and personalized medicine. Epma J. 2015;6:20.
   PubMed Web of Science ®Google Scholar
• Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011;11:723–737.
   PubMed Web of Science ®Google Scholar
• Riabov V, Gudima A, Wang N, et al. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol. 2014;5:75.
   PubMed Web of Science ®Google Scholar
• Shao R, Hamel K, Petersen L, et al. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene. 2009;28:4456–4468.
   PubMed Web of Science ®Google Scholar
• Francescone RA, Scully S, Faibish M, et al. Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J Biol Chem. 2011;286:15332–15343.
   PubMed Web of Science ®Google Scholar
• Faibish M, Francescone R, Bentley B, et al. A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol Cancer Ther. 2011;10:742–751.
   PubMed Web of Science ®Google Scholar
• Junker N, Johansen JS, Andersen CB, et al. Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer. 2005;48:223–231.
   PubMed Web of Science ®Google Scholar
• Sousa S, Brion R, Lintunen M, et al. Human breast cancer cells educate macrophages toward the M2 activation status. Breast Cancer Res. 2015;17:101.
   PubMed Web of Science ®Google Scholar